Related Experiment Videos
Epidermal growth factor receptor expression and measurement in solid tumors
David C Spaulding1, Betsy O Spaulding
1DakoCytomation, Carpinteria, CA 93013, USA.
Abstract:
The efficacies of targeted therapies for cancer treatment are dependent on the expression of the targeted molecule in the tumors of the treated patient population. Immunohistochemistry is an attractive assay format for determining protein expression in biopsies of solid tumors, and is widely used in pathology laboratories. An optimized immunohistochemistry assay for the epidermal growth factor receptor (EGFR) has been developed for the detection of EGFR in colorectal, head and neck, and other tumors that express EGFR, and the assay is being used in colorectal cancer trials of IMC-C225 to select patients for treatment. The specificity of the assay and the detection technology used will be described, along with other assay methodologies and applications for EGFR testing.
Insights
An optimized immunohistochemistry assay detects epidermal growth factor receptor (EGFR) expression in tumors. This assay aids in selecting patients for targeted cancer therapies like IMC-C225 in clinical trials.
Area of Science:
- Oncology
- Pathology
- Biomarker Detection
Background:
- Targeted cancer therapies rely on specific molecular targets within tumors.
- Protein expression levels are critical for predicting treatment efficacy.
- Immunohistochemistry (IHC) is a standard method for assessing protein expression in tumor biopsies.
Purpose of the Study:
- To develop and optimize an immunohistochemistry assay for detecting epidermal growth factor receptor (EGFR).
- To validate the assay's utility in selecting patients for EGFR-targeted cancer therapies.
- To describe the assay's specificity, detection technology, and other applications.
Main Methods:
- Development of an optimized immunohistochemistry assay for EGFR detection.
- Evaluation of assay specificity and the employed detection technology.
- Application of the assay in colorectal cancer clinical trials for patient selection.
Main Results:
- An optimized IHC assay for EGFR detection has been successfully developed.
- The assay is effective in identifying EGFR expression in various tumor types, including colorectal and head and neck cancers.
- The assay is actively used in clinical trials to select patients for IMC-C225 treatment.
Conclusions:
- Optimized IHC assays are crucial for the effective application of targeted cancer therapies.
- EGFR testing using IHC facilitates personalized medicine approaches in oncology.
- This assay provides a reliable method for EGFR detection in diverse solid tumors.